Drug lookup | Fillwise

LORAZEPAM

Form:

21 of 21 products shown

9 general benefit · 2 Limited Use · 10 not a benefit

Other products in the same Health Canada class (N05BA) — coverage varies; not interchangeable

Alprazolam (Xanax): general benefit, Not a benefit
Bromazepam (Lectopam): general benefit, Not a benefit
Chlordiazepoxide (Librium): general benefit, Not a benefit
Clorazepate dipotassium (Tranxene): general benefit, Not a benefit
Diazepam (Diazepam Injection USP): general benefit, Limited Use 481, Not a benefit
Oxazepam (Apo-Oxazepam): general benefit, Not a benefit

2 more in the class list below

Apo-Lorazepam · DIN 00655740 · 0.5mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Apo-Lorazepam · DIN 00655740 Manufacturer: Apotex Inc.; listing date 1996-10-01 Health Canada: Marketed since 1985-12-31 · brand APO-LORAZEPAM · ATC N05BA06 LORAZEPAM · form Tablet · route Oral · ingredients LORAZEPAM 0.5 MG · company Apotex inc · schedule Targeted substances (cdsa iv)

Check this DIN again · Health Canada product record

Apo-Lorazepam: Formulary list price $0.0359/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0359 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6295 · Verify on the e-Formulary ↗ (DIN 00655740)

Source record

DIN 00655740: Apo-Lorazepam Raw flags: sec3=Y Item: 281608136; group id 495; item number 1269; lccId None; manufacturer id APX Source form: Tab; strength: 0.5mg Recorded listing: General benefit Source prices (unrounded): $0.0359; ministry $0.0359 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00655740 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6295

Interchangeable products

Ativan · DIN 02041413 · not recorded PMS-Lorazepam · DIN 00728187 · $0.0359 Teva-Lorazepam · DIN 00711101 · $0.0359

Shortage status: resolved shortage (ended 2026-04-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00655740

Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Lorazepam · DIN 00728187 · 0.5mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

PMS-Lorazepam · DIN 00728187 Manufacturer: Pharmascience Inc.; listing date 2002-04-04 Health Canada: Marketed since 1988-12-31 · brand PMS-LORAZEPAM · ATC N05BA06 LORAZEPAM · form Tablet · route Oral · ingredients LORAZEPAM 0.5 MG · company Pharmascience inc · schedule Targeted substances (cdsa iv)

Check this DIN again · Health Canada product record

PMS-Lorazepam: Formulary list price $0.0359/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0359 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9349 · Verify on the e-Formulary ↗ (DIN 00728187)

Source record

DIN 00728187: PMS-Lorazepam Raw flags: sec3=Y Item: 281608136; group id 495; item number 1269; lccId None; manufacturer id PMS Source form: Tab; strength: 0.5mg Recorded listing: General benefit Source prices (unrounded): $0.0359; ministry $0.0359 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00728187 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9349

Interchangeable products

Apo-Lorazepam · DIN 00655740 · $0.0359 Ativan · DIN 02041413 · not recorded Teva-Lorazepam · DIN 00711101 · $0.0359

Shortage status: resolved shortage (ended 2023-03-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00728187

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Lorazepam · DIN 00711101 · 0.5mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Teva-Lorazepam · DIN 00711101 Manufacturer: Teva Canada Limited; listing date 1996-10-01 Health Canada: Marketed since 2014-01-11 · brand TEVA-LORAZEPAM · ATC N05BA06 LORAZEPAM · form Tablet · route Oral · ingredients LORAZEPAM 0.5 MG · company Teva canada limited · schedule Targeted substances (cdsa iv)

Check this DIN again · Health Canada product record

Teva-Lorazepam: Formulary list price $0.0359/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0359 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=7314 · Verify on the e-Formulary ↗ (DIN 00711101)

Source record

DIN 00711101: Teva-Lorazepam Raw flags: sec3=Y Item: 281608136; group id 495; item number 1269; lccId None; manufacturer id TEV Source form: Tab; strength: 0.5mg Recorded listing: General benefit Source prices (unrounded): $0.0359; ministry $0.0359 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00711101 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=7314

Interchangeable products

Apo-Lorazepam · DIN 00655740 · $0.0359 Ativan · DIN 02041413 · not recorded PMS-Lorazepam · DIN 00728187 · $0.0359

Shortage status: resolved shortage (ended 2025-07-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00711101

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Lorazepam · DIN 00655759 · 1mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Apo-Lorazepam · DIN 00655759 Manufacturer: Apotex Inc.; listing date 1996-10-01 Health Canada: Marketed since 1985-12-31 · brand APO-LORAZEPAM · ATC N05BA06 LORAZEPAM · form Tablet · route Oral · ingredients LORAZEPAM 1 MG · company Apotex inc · schedule Targeted substances (cdsa iv)

Check this DIN again · Health Canada product record

Apo-Lorazepam: Formulary list price $0.0447/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0447 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Source record

DIN 00655759: Apo-Lorazepam Raw flags: sec3=Y Item: 281608098; group id 495; item number 1270; lccId None; manufacturer id APX Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $0.0447; ministry $0.0447 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00655759 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6296

Interchangeable products

Ativan · DIN 02041421 · not recorded PMS-Lorazepam · DIN 00728195 · $0.0447 Teva-Lorazepam · DIN 00637742 · $0.0447

Shortage status: resolved shortage (ended 2024-09-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00655759

Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Lorazepam · DIN 00728195 · 1mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

PMS-Lorazepam · DIN 00728195 Manufacturer: Pharmascience Inc.; listing date 2002-04-04 Health Canada: Marketed since 1988-12-31 · brand PMS-LORAZEPAM · ATC N05BA06 LORAZEPAM · form Tablet · route Oral · ingredients LORAZEPAM 1 MG · company Pharmascience inc · schedule Targeted substances (cdsa iv)

Check this DIN again · Health Canada product record

PMS-Lorazepam: Formulary list price $0.0447/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0447 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9423 · Verify on the e-Formulary ↗ (DIN 00728195)

Source record

DIN 00728195: PMS-Lorazepam Raw flags: sec3=Y Item: 281608098; group id 495; item number 1270; lccId None; manufacturer id PMS Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $0.0447; ministry $0.0447 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00728195 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9423

Interchangeable products

Apo-Lorazepam · DIN 00655759 · $0.0447 Ativan · DIN 02041421 · not recorded Teva-Lorazepam · DIN 00637742 · $0.0447

Shortage status: discontinued (2020-06-15, reported by PHARMASCIENCE INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00728195

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Lorazepam · DIN 00637742 · 1mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Teva-Lorazepam · DIN 00637742 Manufacturer: Teva Canada Limited; listing date 1996-10-01 Health Canada: Marketed since 2014-01-11 · brand TEVA-LORAZEPAM · ATC N05BA06 LORAZEPAM · form Tablet · route Oral · ingredients LORAZEPAM 1 MG · company Teva canada limited · schedule Targeted substances (cdsa iv)

Check this DIN again · Health Canada product record

Teva-Lorazepam: Formulary list price $0.0447/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0447 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6135 · Verify on the e-Formulary ↗ (DIN 00637742)

Source record

DIN 00637742: Teva-Lorazepam Raw flags: sec3=Y Item: 281608098; group id 495; item number 1270; lccId None; manufacturer id TEV Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $0.0447; ministry $0.0447 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00637742 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6135

Interchangeable products

Apo-Lorazepam · DIN 00655759 · $0.0447 Ativan · DIN 02041421 · not recorded PMS-Lorazepam · DIN 00728195 · $0.0447

Shortage status: resolved shortage (ended 2026-02-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00637742

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Lorazepam · DIN 00655767 · 2mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Apo-Lorazepam · DIN 00655767 Manufacturer: Apotex Inc.; listing date 1996-10-01 Health Canada: Marketed since 1985-12-31 · brand APO-LORAZEPAM · ATC N05BA06 LORAZEPAM · form Tablet · route Oral · ingredients LORAZEPAM 2 MG · company Apotex inc · schedule Targeted substances (cdsa iv)

Check this DIN again · Health Canada product record

Apo-Lorazepam: Formulary list price $0.0699/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0699 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Source record

DIN 00655767: Apo-Lorazepam Raw flags: sec3=Y Item: 281608099; group id 495; item number 1271; lccId None; manufacturer id APX Source form: Tab; strength: 2mg Recorded listing: General benefit Source prices (unrounded): $0.0699; ministry $0.0699 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00655767 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6297

Interchangeable products

Ativan · DIN 02041448 · not recorded PMS-Lorazepam · DIN 00728209 · $0.0699 Teva-Lorazepam · DIN 00637750 · $0.0699

Shortage status: resolved shortage (ended 2022-05-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00655767

Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Lorazepam · DIN 00728209 · 2mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

PMS-Lorazepam · DIN 00728209 Manufacturer: Pharmascience Inc.; listing date 2002-04-04 Health Canada: Marketed since 1988-12-31 · brand PMS-LORAZEPAM · ATC N05BA06 LORAZEPAM · form Tablet · route Oral · ingredients LORAZEPAM 2 MG · company Pharmascience inc · schedule Targeted substances (cdsa iv)

Check this DIN again · Health Canada product record

PMS-Lorazepam: Formulary list price $0.0699/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0699 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9424 · Verify on the e-Formulary ↗ (DIN 00728209)

Source record

DIN 00728209: PMS-Lorazepam Raw flags: sec3=Y Item: 281608099; group id 495; item number 1271; lccId None; manufacturer id PMS Source form: Tab; strength: 2mg Recorded listing: General benefit Source prices (unrounded): $0.0699; ministry $0.0699 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00728209 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9424

Interchangeable products

Apo-Lorazepam · DIN 00655767 · $0.0699 Ativan · DIN 02041448 · not recorded Teva-Lorazepam · DIN 00637750 · $0.0699

Shortage status: avoided shortage; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00728209

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Lorazepam · DIN 00637750 · 2mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Teva-Lorazepam · DIN 00637750 Manufacturer: Teva Canada Limited; listing date 1996-10-01 Health Canada: Marketed since 2014-01-11 · brand TEVA-LORAZEPAM · ATC N05BA06 LORAZEPAM · form Tablet · route Oral · ingredients LORAZEPAM 2 MG · company Teva canada limited · schedule Targeted substances (cdsa iv)

Check this DIN again · Health Canada product record

Teva-Lorazepam: Formulary list price $0.0699/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0699 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6136 · Verify on the e-Formulary ↗ (DIN 00637750)

Source record

DIN 00637750: Teva-Lorazepam Raw flags: sec3=Y Item: 281608099; group id 495; item number 1271; lccId None; manufacturer id TEV Source form: Tab; strength: 2mg Recorded listing: General benefit Source prices (unrounded): $0.0699; ministry $0.0699 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00637750 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6136

Interchangeable products

Apo-Lorazepam · DIN 00655767 · $0.0699 Ativan · DIN 02041448 · not recorded PMS-Lorazepam · DIN 00728209 · $0.0699

Shortage status: resolved shortage (ended 2026-03-25); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00637750

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lorazepam Injection USP · DIN 02243278 · 4mg/mL · injection solution (with preservative)

Limited Use — Reason for Use code 481 requiredMarketed · checked 2026-09-02

StatusLimited Use — Reason for Use code 481 required

Write on scriptLU code 481 (patient must meet the criteria below)

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ontario Limited Use criteria — code 481

Reason for Use code 481 For the management of patients receiving palliative care*. Coverage limit: LU Authorization Period: 1 year Coverage limit: *The patient must have a progressive life-limiting illness and require this medication for palliative purposes.

1 brand, same coverage

Lorazepam Injection USP · DIN 02243278 Manufacturer: Sandoz Canada Inc.; listing date 2017-02-28 Health Canada: Marketed since 2005-09-21 · brand LORAZEPAM INJECTION USP · ATC N05BA06 LORAZEPAM · form Solution · route Intravenous, Intramuscular · ingredients LORAZEPAM 4 MG/ML · company Sandoz canada incorporated · schedule Targeted substances (cdsa iv)

Check this DIN again · Health Canada product record

Lorazepam Injection USP: Formulary list price $19.0800/unit (unit not stated in source; not the patient's cost)

Ministry pays: $19.0800 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67176 · Verify on the e-Formulary ↗ (DIN 02243278)

Source record

DIN 02243278: Lorazepam Injection USP Raw flags: sec12=Y, sec3=Y Item: 282400076; group id 522; item number 1412; lccId 00275; manufacturer id SDZ Source form: Inj Sol (with preservative); strength: 4mg/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $19.0800; ministry $19.0800 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02243278 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67176

Interchangeable products

Ativan · DIN 02041405 · not recorded Lorazepam Injection, USP · DIN 02550962 · $19.0800

Shortage status: resolved shortage (ended 2026-06-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02243278

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lorazepam Injection, USP · DIN 02550962 · 4mg/mL · injection solution (with preservative)

Limited Use — Reason for Use code 481 requiredMarketed · checked 2026-09-02

StatusLimited Use — Reason for Use code 481 required

Write on scriptLU code 481 (patient must meet the criteria below)

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ontario Limited Use criteria — code 481

1 brand, same coverage

Lorazepam Injection, USP · DIN 02550962 Manufacturer: Fresenius Kabi Canada Ltd.; listing date 2026-01-30 Health Canada: Marketed since 2026-01-20 · brand LORAZEPAM INJECTION, USP · ATC N05BA06 LORAZEPAM · form Solution · route Intravenous, Intramuscular · ingredients LORAZEPAM 4 MG/ML · company Fresenius kabi canada ltd · schedule Targeted substances (cdsa iv)

Check this DIN again · Health Canada product record

Lorazepam Injection, USP: Formulary list price $19.0800/unit (unit not stated in source; not the patient's cost)

Ministry pays: $19.0800 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103972 · Verify on the e-Formulary ↗ (DIN 02550962)

Source record

DIN 02550962: Lorazepam Injection, USP Raw flags: sec12=Y, sec3=Y Item: 282400076; group id 522; item number 1412; lccId 00275; manufacturer id FKC Source form: Inj Sol (with preservative); strength: 4mg/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $19.0800; ministry $19.0800 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02550962 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103972

Interchangeable products

Ativan · DIN 02041405 · not recorded Lorazepam Injection USP · DIN 02243278 · $19.0800

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02550962

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lorazepam Sublingual · DIN 02410745 · 0.5mg · SL tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

StatusOff-Formulary Interchangeable, not an ODB benefit

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Lorazepam Sublingual · DIN 02410745 Manufacturer: A A Pharma Inc.; listing date 2013-10-31 Health Canada: Marketed since 2018-01-15 · brand LORAZEPAM SUBLINGUAL · ATC N05BA06 LORAZEPAM · form Tablet · route Sublingual · ingredients LORAZEPAM 0.5 MG · company Aa pharma inc · schedule Targeted substances (cdsa iv)

Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89541 · Verify on the e-Formulary ↗ (DIN 02410745)

Source record

DIN 02410745: Lorazepam Sublingual Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 282400078; group id 523; item number 1413; lccId None; manufacturer id AAP Source form: SL Tab; strength: 0.5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.1099; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02410745 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89541

Interchangeable products

Ativan · DIN 02041456 · not recorded

Shortage status: anticipated shortage (last updated 2026-08-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02410745

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lorazepam Sublingual · DIN 02410753 · 1mg · SL tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

StatusOff-Formulary Interchangeable, not an ODB benefit

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Lorazepam Sublingual · DIN 02410753 Manufacturer: A A Pharma Inc.; listing date 2013-10-31 Health Canada: Marketed since 2018-01-15 · brand LORAZEPAM SUBLINGUAL · ATC N05BA06 LORAZEPAM · form Tablet · route Sublingual · ingredients LORAZEPAM 1 MG · company Aa pharma inc · schedule Targeted substances (cdsa iv)

Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89542 · Verify on the e-Formulary ↗ (DIN 02410753)

Source record

DIN 02410753: Lorazepam Sublingual Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 282400169; group id 523; item number 1414; lccId None; manufacturer id AAP Source form: SL Tab; strength: 1mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.1385; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02410753 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89542

Interchangeable products

Ativan · DIN 02041464 · not recorded

Shortage status: resolved shortage (ended 2026-08-21); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02410753

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lorazepam Sublingual · DIN 02410761 · 2mg · SL tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

StatusOff-Formulary Interchangeable, not an ODB benefit

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Lorazepam Sublingual · DIN 02410761 Manufacturer: A A Pharma Inc.; listing date 2013-10-31 Health Canada: Marketed since 2018-01-15 · brand LORAZEPAM SUBLINGUAL · ATC N05BA06 LORAZEPAM · form Tablet · route Sublingual · ingredients LORAZEPAM 2 MG · company Aa pharma inc · schedule Targeted substances (cdsa iv)

Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89543 · Verify on the e-Formulary ↗ (DIN 02410761)

Source record

DIN 02410761: Lorazepam Sublingual Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 282400079; group id 523; item number 1415; lccId None; manufacturer id AAP Source form: SL Tab; strength: 2mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.2152; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02410761 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89543

Interchangeable products

Ativan · DIN 02041472 · not recorded

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ativan · DIN 02041456 · 0.5mg · SL tablet

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2026-07-03 — choose a marketed DIN from the same-category list.Discontinued 2026-07-03 · checked 2026-09-02

StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2026-07-03 — choose a marketed DIN from the same-category list.

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2026-07-03 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Ativan · DIN 02041456 Manufacturer: Pfizer Canada Inc.; listing date 2013-10-31 Health Canada: Cancelled post market since 2026-07-03 · brand ATIVAN · ATC N05BA06 LORAZEPAM · form Tablet · route Sublingual · ingredients LORAZEPAM 0.5 MG · company Pfizer canada ulc · schedule Targeted substances (cdsa iv)

Check this DIN again · Health Canada product record

Ativan: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17817 · Verify on the e-Formulary ↗ (DIN 02041456)

Source record

DIN 02041456: Ativan Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 282400078; group id 523; item number 1413; lccId None; manufacturer id PFI Source form: SL Tab; strength: 0.5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02041456 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17817

Interchangeable products

Lorazepam Sublingual · DIN 02410745 · not recorded

Shortage status: discontinued (2026-02-27, reported by PFIZER CANADA ULC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02041456

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2026-07-03 — choose a marketed DIN from the same-category list.

Ativan · DIN 02041413 · 0.5mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2025-11-05 — choose a marketed DIN from the same-category list.Discontinued 2025-11-05 · checked 2026-09-02

StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2025-11-05 — choose a marketed DIN from the same-category list.

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2025-11-05 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Ativan · DIN 02041413 Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2025-11-05 · brand ATIVAN · ATC N05BA06 LORAZEPAM · form Tablet · route Oral · ingredients LORAZEPAM 0.5 MG · company Pfizer canada ulc · schedule Targeted substances (cdsa iv)

Check this DIN again · Health Canada product record

Ativan: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16589 · Verify on the e-Formulary ↗ (DIN 02041413)

Source record

DIN 02041413: Ativan Raw flags: notABenefit=Y, sec3=Y Item: 281608136; group id 495; item number 1269; lccId None; manufacturer id PFI Source form: Tab; strength: 0.5mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02041413 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16589

Interchangeable products

Apo-Lorazepam · DIN 00655740 · $0.0359 PMS-Lorazepam · DIN 00728187 · $0.0359 Teva-Lorazepam · DIN 00711101 · $0.0359

Shortage status: discontinued (2025-10-31, reported by PFIZER CANADA ULC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02041413

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2025-11-05 — choose a marketed DIN from the same-category list.

Ativan · DIN 02041464 · 1mg · SL tablet

StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2026-07-03 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Ativan · DIN 02041464 Manufacturer: Pfizer Canada Inc.; listing date 2013-10-31 Health Canada: Cancelled post market since 2026-07-03 · brand ATIVAN · ATC N05BA06 LORAZEPAM · form Tablet · route Sublingual · ingredients LORAZEPAM 1 MG · company Pfizer canada ulc · schedule Targeted substances (cdsa iv)

Check this DIN again · Health Canada product record

Ativan: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16118 · Verify on the e-Formulary ↗ (DIN 02041464)

Source record

DIN 02041464: Ativan Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 282400169; group id 523; item number 1414; lccId None; manufacturer id PFI Source form: SL Tab; strength: 1mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02041464 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16118

Interchangeable products

Lorazepam Sublingual · DIN 02410753 · not recorded

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2026-07-03 — choose a marketed DIN from the same-category list.

Ativan · DIN 02041421 · 1mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2025-11-05 — choose a marketed DIN from the same-category list.Discontinued 2025-11-05 · checked 2026-09-02

StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2025-11-05 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Ativan · DIN 02041421 Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2025-11-05 · brand ATIVAN · ATC N05BA06 LORAZEPAM · form Tablet · route Oral · ingredients LORAZEPAM 1 MG · company Pfizer canada ulc · schedule Targeted substances (cdsa iv)

Check this DIN again · Health Canada product record

Ativan: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16588 · Verify on the e-Formulary ↗ (DIN 02041421)

Source record

DIN 02041421: Ativan Raw flags: notABenefit=Y, sec3=Y Item: 281608098; group id 495; item number 1270; lccId None; manufacturer id PFI Source form: Tab; strength: 1mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02041421 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16588

Interchangeable products

Apo-Lorazepam · DIN 00655759 · $0.0447 PMS-Lorazepam · DIN 00728195 · $0.0447 Teva-Lorazepam · DIN 00637742 · $0.0447

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2025-11-05 — choose a marketed DIN from the same-category list.

Ativan · DIN 02041472 · 2mg · SL tablet

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2024-12-29 — choose a marketed DIN from the same-category list.Discontinued 2024-12-29 · checked 2026-09-02

StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2024-12-29 — choose a marketed DIN from the same-category list.

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2024-12-29 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Ativan · DIN 02041472 Manufacturer: Pfizer Canada Inc.; listing date 2013-10-31 Health Canada: Cancelled post market since 2024-12-29 · brand ATIVAN · ATC N05BA06 LORAZEPAM · form Tablet · route Sublingual · ingredients LORAZEPAM 2 MG · company Pfizer canada ulc · schedule Targeted substances (cdsa iv)

Check this DIN again · Health Canada product record

Ativan: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16586 · Verify on the e-Formulary ↗ (DIN 02041472)

Source record

DIN 02041472: Ativan Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 282400079; group id 523; item number 1415; lccId None; manufacturer id PFI Source form: SL Tab; strength: 2mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02041472 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16586

Interchangeable products

Lorazepam Sublingual · DIN 02410761 · not recorded

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2024-12-29 — choose a marketed DIN from the same-category list.

Ativan · DIN 02041448 · 2mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2025-11-05 — choose a marketed DIN from the same-category list.Discontinued 2025-11-05 · checked 2026-09-02

StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2025-11-05 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Ativan · DIN 02041448 Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2025-11-05 · brand ATIVAN · ATC N05BA06 LORAZEPAM · form Tablet · route Oral · ingredients LORAZEPAM 2 MG · company Pfizer canada ulc · schedule Targeted substances (cdsa iv)

Check this DIN again · Health Canada product record

Ativan: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16587 · Verify on the e-Formulary ↗ (DIN 02041448)

Source record

DIN 02041448: Ativan Raw flags: notABenefit=Y, sec3=Y Item: 281608099; group id 495; item number 1271; lccId None; manufacturer id PFI Source form: Tab; strength: 2mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02041448 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16587

Interchangeable products

Apo-Lorazepam · DIN 00655767 · $0.0699 PMS-Lorazepam · DIN 00728209 · $0.0699 Teva-Lorazepam · DIN 00637750 · $0.0699

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2025-11-05 — choose a marketed DIN from the same-category list.

Ativan · DIN 02041405 · 4mg/mL · injection solution (with preservative)

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2005-01-19 — choose a marketed DIN from the same-category list.Discontinued 2005-01-19 · checked 2026-09-02

StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2005-01-19 — choose a marketed DIN from the same-category list.

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2005-01-19 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ontario Limited Use criteria — code 481

1 brand, same coverage

Ativan · DIN 02041405 Manufacturer: Wyeth Pharmaceuticals; listing date 2017-02-28 Health Canada: Cancelled post market since 2005-01-19 · brand ATIVAN INJECTION LIQ 4MG/ML · ATC N05BA06 LORAZEPAM · form Solution · route Intravenous, Intramuscular · ingredients LORAZEPAM 4 MG/ML · company Wyeth canada · schedule Targeted substances (cdsa iv)

Check this DIN again · Health Canada product record

Ativan: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15616 · Verify on the e-Formulary ↗ (DIN 02041405)

Source record

DIN 02041405: Ativan Raw flags: notABenefit=Y, sec3=Y Item: 282400076; group id 522; item number 1412; lccId 00275; manufacturer id WAY Source form: Inj Sol (with preservative); strength: 4mg/mL Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02041405 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15616

Interchangeable products

Lorazepam Injection USP · DIN 02243278 · $19.0800 Lorazepam Injection, USP · DIN 02550962 · $19.0800

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2005-01-19 — choose a marketed DIN from the same-category list.

Other drugs in the same formulary classes and how they are covered

Other drugs in the same formulary class (28:16:08 Tranquilizers) and how they are covered

Matched class: 28:16:08 Tranquilizers

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ARIPIPRAZOLE, ASENAPINE, BREXPIPRAZOLE, CARIPRAZINE, FLUPENTIXOL DECANOATE, FLUPENTIXOL DIHYDROCHLORIDE, PALIPERIDONE, PALIPERIDONE PALMITATE, PERICYAZINE, PIMOZIDE, ZIPRASIDONE HCL MONOHYDRATE, ZUCLOPENTHIXOL DECANOATE, ZUCLOPENTHIXOL DIHYDROCHLORIDE Some products covered without a code (check the product listing): ALPRAZOLAM, BROMAZEPAM, CHLORDIAZEPOXIDE, CHLORPROMAZINE, CLORAZEPATE DIPOTASSIUM, DIAZEPAM, FLUPHENAZINE HCL, HALOPERIDOL, HALOPERIDOL DECANOATE, LOXAPINE SUCCINATE, LURASIDONE HYDROCHLORIDE, OLANZAPINE, OXAZEPAM, PERPHENAZINE, PROCHLORPERAZINE, QUETIAPINE, RISPERIDONE, TRIFLUOPERAZINE 28:16:08 Tranquilizers

ALPRAZOLAM

· 12 products · General benefit (6), Off-Formulary Interchangeable, not an ODB benefit (6) · strengths: 0.25mg, 0.5mg, 1mg, 2mg · Tab

BROMAZEPAM

· 8 products · Listed, not a benefit (3), General benefit (5) · strengths: 1.5mg, 3mg, 6mg · Tab

CHLORDIAZEPOXIDE

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 5mg, 10mg, 25mg · Cap

CLORAZEPATE DIPOTASSIUM

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 3.75mg, 7.5mg, 15mg · Cap

DIAZEPAM

· 10 products · Limited Use, codes 481 (1), General benefit (6), Listed, not a benefit (3) · strengths: 5mg/mL, 10mg/2mL, 15mg/3mL, 2mg, 5mg, 10mg · Inj Sol (Preservative Free), Rect Gel-2x 5mg Pk, Rect Gel-2x10mg Pk, Rect Gel-2x15mg Pk, Tab

OXAZEPAM

· 6 products · General benefit (3), Listed, not a benefit (3) · strengths: 10mg, 15mg, 30mg · Tab

HYDROXYZINE HCL

· 8 products · Listed, not a benefit · strengths: 10mg, 25mg, 50mg · Cap

ARIPIPRAZOLE

· 70 products · General benefit · strengths: 720mg/2.4mL, 960mg/3.2mL, 300mg/Vial, 400mg/Vial, 2mg, 5mg, 10mg, 15mg, 20mg, 30mg · Inj Sol-Pref Syr, Prolong-Rel Inj Pd-Vial Pk, Tab

ASENAPINE

· 2 products · General benefit · strengths: 5mg, 10mg · SL Tab

BREXPIPRAZOLE

· 6 products · General benefit · strengths: 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg · Tab

CARIPRAZINE

· 4 products · General benefit · strengths: 1.5mg, 3mg, 4.5mg, 6mg · Cap

CHLORPROMAZINE

· 6 products · General benefit (3), Listed, not a benefit (3) · strengths: 25mg, 50mg, 100mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:16:08 and 21 more

Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists

Other drugs in the same formulary class (28:24 Sedatives and Hypnotics) and how they are covered

Matched class: 28:24 Sedatives and Hypnotics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: NITRAZEPAM, PHENOBARBITAL, TEMAZEPAM Some products covered without a code (check the product listing): BUSPIRONE HYDROCHLORIDE, FLURAZEPAM, METHOTRIMEPRAZINE, TRIAZOLAM 28:24 Sedatives and Hypnotics

BUSPIRONE HYDROCHLORIDE

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 10mg · Tab

FLURAZEPAM

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 15mg, 30mg · Cap

METHOTRIMEPRAZINE

· 9 products · General benefit (5), Listed, not a benefit (4) · strengths: 25mg/mL, 2mg, 5mg, 25mg, 50mg · Inj Sol-1mL Pk, Tab

NITRAZEPAM

· 2 products · General benefit · strengths: 5mg, 10mg · Tab

PHENOBARBITAL

· 5 products · General benefit · strengths: 5mg/mL, 15mg, 30mg, 60mg, 100mg · Oral Elixir, Tab

TEMAZEPAM

· 2 products · General benefit · strengths: 15mg, 30mg · Cap

TRIAZOLAM

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 0.125mg, 0.25mg · Tab

MIDAZOLAM

· 3 products · Listed, not a benefit (1), Limited Use, codes 495, 496 (2) · strengths: 5mg/mL · Inj Sol (with Preservative)

ESZOPICLONE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1mg, 2mg, 3mg · Tab

ZOLPIDEM TARTRATE

· 10 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 5mg, 10mg · SL Tab

ZOPICLONE

· 40 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 3.75mg, 5mg, 7.5mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:24

Full class listing Related classes: 28:08 Analgesics, 28:10 Opiate Antagonists, 28:12 Anticonvulsants, 28:16 Psychotherapeutic Agents, 28:20 C.N.S. Stimulants, 28:36 Antiparkinsonian Agents, 28:92 Miscellaneous Central Nervous System Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.

Other drugs whose Health Canada label lists a similar indication: anxiety neurosis

From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. OXAZEPAM · General benefit (3), Listed, not a benefit (3) 1 INDICATIONS APO-OXAZEPAM (oxazepam tablets) is indicated for the short-term symptomatic relief of excessive anxiety and tension in patients with anxiety neurosis. PM: https://pdf.hres.ca/dpd_pm/00072522.PDF; date SEP 05, 2023; DIN 00402680; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26

What the Health Canada label says it is for

1 INDICATIONS TEVA-LORAZEPAM (lorazepam) is indicated for: • the short-term relief of manifestations of excessive anxiety in patients with anxiety neurosis. Anxiety and tension associated with the stresses of everyday life usually do not require treatment with anxiolytic drugs. 1.1 Pediatrics Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness. Long-term use of TEVA-LORAZEPAM should be avoided in geriatric patients. Enhanced monitoring is recommended (see 7 WARNINGS AND PRECAUTIONS, Falls and fractures; 4 DOSAGE AND ADMINISTRATION, 4.1 Dosing considerations). https://pdf.hres.ca/dpd_pm/00070208.PDF PM date: March 05, 1985 Source product: TEVA-LORAZEPAM; DIN 00637742; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

PMS-Lorazepam · DIN 00728195 Shortage status: discontinued (2020-06-15, reported by PHARMASCIENCE INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00728195

Check this DIN again

Ativan · DIN 02041456 Shortage status: discontinued (2026-02-27, reported by PFIZER CANADA ULC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02041456

Check this DIN again

Ativan · DIN 02041413 Shortage status: discontinued (2025-10-31, reported by PFIZER CANADA ULC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02041413

Check this DIN again

Ativan · DIN 02041464 Shortage status: discontinued (2026-02-27, reported by PFIZER CANADA ULC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02041464

Check this DIN again

Ativan · DIN 02041421 Shortage status: discontinued (2025-10-31, reported by PFIZER CANADA ULC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02041421

Check this DIN again

Ativan · DIN 02041472 Shortage status: discontinued (2025-10-31, reported by PFIZER CANADA ULC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02041472

Check this DIN again

Ativan · DIN 02041448 Shortage status: discontinued (2025-10-31, reported by PFIZER CANADA ULC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02041448

Check this DIN again

Other review policies

For Lorazepam Sublingual, Ativan: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote

Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote

Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026